The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

celatorpharma.com

Founded Year

2000

Stage

Acq - P2P | Acquired

Total Raised

$156.25M

Valuation

$0000 

About Celator Pharmaceuticals

Celator Pharmaceuticals is a pharmaceutical company developing new and effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents an approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage product, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory.

Celator Pharmaceuticals Headquarter Location

303B College Road East

Princeton, New Jersey, 08540,

United States

609-243-0123

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Celator Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Celator Pharmaceuticals is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Celator Pharmaceuticals Patents

Celator Pharmaceuticals has filed 26 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Antineoplastic drugs
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/17/2020

6/8/2021

Transcription factors, Experimental cancer drugs, Proteins, Human proteins, Monoclonal antibodies

Grant

Application Date

1/17/2020

Grant Date

6/8/2021

Title

Related Topics

Transcription factors, Experimental cancer drugs, Proteins, Human proteins, Monoclonal antibodies

Status

Grant

Latest Celator Pharmaceuticals News

Expansion Therapeutics Appoints Gary Bridger, Ph.D., to Its Board of Directors

Jan 19, 2022

01/19/2022 | 07:31am EST Message : --Recognized industry leader brings deep scientific and operational experience to Expansion board Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the appointment of Gary Bridger, Ph.D., to its Board of Directors, serving as an independent director. Dr. Bridger has more than 30 years of experience in research and development and a breadth of management and operational experience, having served in senior leadership positions and on the boards for several leading biotechnology and pharmaceutical companies. He currently serves as interim Chief Scientific Officer and independent board member for Liminal Biosciences, as well as an independent board member for X4 Pharmaceuticals. “We are excited to work with Dr. Bridger and welcome his strategic insight, research knowledge and clinical experience to advance the development of our pipeline of small molecule medicines for severe RNA-mediated neurodegenerative diseases,” said Renato Skerlj, Ph.D., Chief Executive Officer and President of Expansion Therapeutics. “In addition to his broad experience, he also shares in our company’s goal of helping patients with neurodegenerative diseases who currently have limited or no treatment options.” “We look forward to collaborating and working alongside Dr. Bridger to position Expansion as the leading company in developing transformative oral medicines for severe RNA-mediated diseases,” said Scott Rocklage, Ph.D., Board Chairman. Most recently, Dr. Bridger served on the Board of Directors for Aquinox Pharmaceuticals from 2015 until the company merged with Neoleukin Therapeutics in 2019. Prior to that, he was Managing Director at Five Corners Capital, where he was involved in several initial public offerings (IPOs) on the Nasdaq for portfolio companies, including Alder Biopharmaceuticals, Aquinox Pharmaceuticals, Celator Pharmaceuticals, MacroGenics Inc., and Xenon Pharmaceuticals. He also has served on the boards for Alder, Aquinox, Neuraxon Inc. and was a board observer for Celator and Presidio Pharmaceuticals. “I believe Expansion’s differentiated platform holds tremendous promise in delivering disease-modifying therapies to treat a wide range of RNA-mediated diseases, particularly neurodegenerative diseases,” said Dr. Bridger. “I look forward to working closely with Expansion’s leadership team and Board of Directors to elevate its strategy and operations as the company grows and progresses its pipeline of novel RNA-targeted drug candidates through preclinical and clinical development.” Before joining Five Corners Capital, Dr. Bridger was Executive Vice President of Research and Development for Xenon Pharmaceuticals Inc., developing innovative therapies for neurological disorders, including epilepsy. Previously, he served as a partner at Ventures West Capital Management where he provided scientific and operational expertise to life sciences companies. Dr. Bridger has also held senior positions at Genzyme Corporation and AnorMED Inc. While at Genzyme, he was directly involved in the successful regulatory filing, approval and launch of Mozobil®(plerixafor), in the U.S., Europe and Canada. He began his pharmaceutical career at Johnson Matthey Pharmaceutical Research. Dr. Bridger received his B.Sc. in Chemistry and his Ph.D. in Synthetic Organic Chemistry from the University of Manchester Institute of Science and Technology (UMIST), in Manchester, UK. He completed his post-doctoral research fellowship in Organic Chemistry at Boston College. He has authored more than 90 peer-reviewed publications and has over 40 issued patents. About Expansion Therapeutics Expansion Therapeutics is a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases including neurodegenerative disorders. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at Scripps Research, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule RNA modulators. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of severe RNA-mediated disease indications. Headquartered in Boston, Massachusetts, Expansion’s research facility is located in Jupiter, Florida. For more information, visit www.expansionrx.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005257/en/ © Business Wire 2022

You May Also Like

Longevica Logo
Longevica

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

A
Ascenta Therapeutics

Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).On June 7, 2010, Ascenta Therapeutics was acquired by Sanofi at a valuation of $398M.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

S
Symphony Medical

Symphony Medical is a biopharmaceutical company focused on non-destructive treatments for cardiac conduction abnormalities using cellular-based or biopolymer-based therapies.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

R
RealBio Technology

RealBio Technology is working on the commercialization of a cell and tissue culture technology for drug discovery and life science research. The RealBio D4 Culture System facilitates the growth of in vitro cultures that mimic the natural composition, configuration and function of normal and diseased tissue. The design ensures that cells can be cultured with an ideal mixture of gas and nutrients, delivered independently, to promote healthy, consistent growth, improving the culture quality. Results from testing indicate that our system outperforms other available 2D and 3D technologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.